Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer

Published online August 10, 2017, DOI: 10.1200/JOP.2017.024919

Sam S. Chang, Bernard H. Bochner, Roger Chou, Robert Dreicer, Ashish M. Kamat, Seth P. Lerner, Yair Lotan, Joshua J. Meeks, Jeff M. Michalski, Todd M. Morgan, Diane Z. Quale, Jonathan E. Rosenberg, Anthony L. Zietman, and Jeffrey M. Holzbeierlein

Although representing approximately 25% of patients diagnosed with bladder cancer, muscle-invasive bladder cancer carries a significant risk of death that has not changed significantly in decades. Increasingly, clinicians and patients recognize the importance of multidisciplinary collaborative efforts that take into account survival and quality-of-life concerns. For the first time for any type of malignancy, the American Urological Association, the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology have formulated an evidence-based guideline.¹ The guideline provides a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer and is designed to be used in conjunction with the associated treatment algorithm.

Patient information is available at www.cancer.net.

© 2019 American Society of Clinical Oncology, all rights reserved. For licensing opportunities, contact licensing@asco.org.